Global Kawasaki Disease Treatment Market, By Treatment (Gamma Globulin, Monoclonal Antibodies, Steroids, NSAIDs), Route of Administration (Oral, Parenteral, Others), End-Users (Clinics, Hospitals, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights : Global Kawasaki Disease Treatment Market
Kawasaki disease treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 6.80% in the above-mentioned research forecast period. Rapid rise in incidence of kawasaki disease in the emerging countries and increase in adoption of intravenous immunoglobulin therapy in order to prevent or reduce the coronary artery problem are some factors driving the market growth.
Moreover, increasing focus of market players towards the development of advanced treatment options and the underlining clinical trials using different drugs such as steroids and infliximab to treat the disease as the second line and tertiary treatment also boost up the market growth. Moreover, increasing research and development and rising healthcare expenditure act as opportunities for the market growth. But,, sometimes adverse effect related to the drugs, strict regulatory framework and high cost of biological therapy among others may hamper the global Kawasaki disease treatment market.
Kawasaki disease is a kind of mucocutaneous lymph node syndrome which is most commonly observed among the children and reported to affect their blood vessels. The disease has also been reported to affect the lymph nodes and causes symptoms in affected person’s mouth, nose and throat. This disease is a common cause of children’s heart disease. The condition mostly affects the children younger than 5 years old. As per the Kawasaki Disease Foundation (KDF), Kawasaki Disease affects approximately more than 4,200 children in U.S each year. Moreover the disease is more common in boys as compared to that of the girls. In some Asian countries the disease reaches the peak value during the middle of summer. The early symptoms reported among the patients includes high fever, rashes on the torso and groin, swollen lymph nodes, swollen hands, red palms among others. Other late stage symptoms includes abdominal pain, vomiting, diarrhoea, enlarged gall bladder among others.
As per the report published by NCBI entitled “Kawasaki Disease: Global Burden and Genetic Background” the incidence data of Kawasaki Disease varies from 7.06 to 55.1 per 100,000 children worldwide. Moreover, the report also suggested that in Japan 1 in every 100 children suffers from Kawasaki Disease by the age of 5. This affected population largely dependent upon the effective treatment approach and hence expected to provide market with the lucrative growth. It is also estimated that Kawasaki disease treatment market is growing with the CAGR of 6.80% in 2020.
This Kawasaki disease treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Kawasaki Disease Treatment Market Scope and Market Size
Kawasaki disease treatment market is segmented on the basis of treatment, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of treatment, the Kawasaki disease treatment market is segmented into gamma globulin, monoclonal antibodies, steroids, etanercept, NSAIDs. Monoclonal antibodies is further segmented into infliximab, adalimumab, certolizumab pegol and golimumab. NSAIDs is further-segmented into aspirin among others.
- On the basis of route of administration, the Kawasaki disease treatment market is segmented into oral, parenteral and others.
- On the basis of end-users, the Kawasaki disease treatment market is segmented into clinics, hospitals, homecare, others.
- On the basis of distribution channel, the Kawasaki disease treatment market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy, others.
Kawasaki Disease Treatment Market Country Level Analysis
Kawasaki disease treatment market is analysed and market size information is provided by country, treatment, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Kawasaki disease treatment market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share due to the rising cases of Kawasaki disease in the U.S with reported 4,200 children in the U.S every year. Moreover, rising governmental concern towards the children health and increasing research and development activities is also boosting the growth of market. Asia-Pacific is expected to account for the largest market share owing to increase in incidence of acquired congenital heart disease caused due to Kawasaki disease. Moreover, increasing prevalence of KD in Japan with reported 1 affected child in every 100 children is another factor boosting the Asia Pacific market.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Kawasaki disease treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Kawasaki Disease Treatment Market Share Analysis
Kawasaki disease treatment market competitive landscape provides details by competitor details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Kawasaki disease treatment market.
The major players covered in the Kawasaki disease treatment market are Takeda Pharmaceutical Company Limited, CSL, Grifols, S.A., LFB Biomedicaments S.A., Kedrion S.p.A., Octapharma AG, Sanquin Plasma Products B.V., Bayer AG, and Novartis AG among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.